Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Lung Cancer. 2017 Mar 29;108:173–182. doi: 10.1016/j.lungcan.2017.03.017

Table 3.

Subgroup analysis comparing concurrent-consolidation to concurrent-alone for patients treated with a carboplatin- or cisplatin-based chemotherapy regimen during the concurrent phase of chemoradiation. Hazard ratios for overall survival (OS) and cancer-specific survival (CSS) were determined from inverse probability of treatment weighting analysis, with a hazard ratio <1 representing a benefit with concurrent-consolidation. Propensity scores were used to represent probability of treatment.

OS CSS
HR 95% CI P HR 95% CI P
Carboplatin-paclitaxel/docetaxel 0.83 (0.73–0.95) 0.006 0.85 (0.74–0.98) 0.02
Cisplatin-etoposide 0.91 (0.60–1.40) 0.67 0.89 (0.57–1.41) 0.63